Quince Therapeutics

NASDAQ: QNCX
Nasdaq Stock Market
Healthcare Biotechnology
Global Rank
#38213
Country Rank
#4927
Market Cap
18.26 M
Price
18.67
Change (%)
0.48%
Volume
61,735

Quince Therapeutics's latest marketcap:

18.26 M

As of 07/17/2026, Quince Therapeutics's market capitalization has reached $18.26 M. According to our data, Quince Therapeutics is the 38213th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 18.26 M
Revenue (ttm) 0
Net Income (ttm) -36,155,000
Shares Out 977,962
EPS (ttm) -137.27
Forward PE 0.00
Ex-Dividend Date n/a
Earnings Date 08/10/2026
Market Cap Chart
Data Updated: 07/17/2026

Quince Therapeutics's yearly market capitalization.

Quince Therapeutics has seen its market value drop from $1.51 B to $18.26 M since 2019, representing a total decrease of 98.79% and an annual compound decline rate (CAGR) of 49.05%.
Date Market Cap($) Change (%) Global Rank
07/17/2026 $18.26 M -91.86% 38213
12/31/2025 $186.53 M 126.7% 26705
12/31/2024 $82.28 M 82.8% 24576
12/29/2023 $45.01 M 95.46% 28472
12/30/2022 $23.03 M -93.89% 31844
12/31/2021 $377.06 M -53.99% 15100
12/31/2020 $819.45 M -45.64% 8916
12/31/2019 $1.51 B n/a

Company Profile

About Quince Therapeutics, Inc.

Quince Therapeutics, Inc. is a biopharmaceutical company dedicated to acquiring, developing, and commercializing innovative therapeutics for patients suffering from debilitating and rare diseases.

Key Focus Areas

  • Lead Asset: EryDex, a promising candidate for treating rare pediatric neurodegenerative diseases, including Ataxia-Telangiectasia (A-T), an inherited disorder caused by mutations in the ATM gene.
  • AIDE Technology Platform: A cutting-edge drug/device combination platform that automates the encapsulation of drugs into a patient’s red blood cells. The platform includes:
    • Automated equipment (RCL)
    • Sterile single-use consumable treatment kits (EryKit, Syringe Kit)
    • Drugs and process solutions

Company Background

Formerly known as Cortexyme, Inc., the company rebranded as Quince Therapeutics, Inc. in August 2022. Founded in 2012, Quince Therapeutics is headquartered in South San Francisco, California.

Frequently Asked Questions

  • What is Quince Therapeutics's (QNCX) current market cap?
    As of 07/17/2026, Quince Therapeutics (including the parent company, if applicable) has an estimated market capitalization of $18.26 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
  • Quince Therapeutics global market capitalization ranking is approximately 38213 as of 07/17/2026. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

MarketCapWatch.com ranks all listed companies worldwide, providing unique insights into market capitalization across industries. As one of the most comprehensive ranking platforms, it covers companies of all sizes and sectors.

Research Tools

Copyright © 2026. All rights reserved

Important Disclaimer: All content provided on this website, including hyperlinked pages, related applications, forums, blogs, social media accounts, and other platforms ("the Site"), is for general informational purposes only and sourced from third-party providers. We make no guarantees regarding the accuracy, completeness, or timeliness of the content.

None of the information presented constitutes financial, legal, or professional advice. Users should conduct their own research, evaluation, and verification before making any decisions. Investing and trading carry significant risks that may lead to substantial losses. Therefore, we strongly recommend consulting a qualified financial advisor before taking any action.